This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, G. C.
Right arrow Articles by Brown, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, G. C.
Right arrow Articles by Brown, H. C.
Related Collections
Right arrow Ophthalmology

PEDIATRICS Vol. 104 No. 4 October 1999, p. e47

ELECTRONIC ARTICLE:
Cost-Effectiveness of Treatment for Threshold Retinopathy of Prematurity

Received Dec 31, 1998; accepted Apr 26, 1999.

Gary C. Brown*, Dagger , Melissa M. Brown*, §, Sanjay Sharma*, parallel , William TasmanDagger , and Heidi C. Brown*

From the * Center for Evidence-Based Healthcare, Flourtown, Pennsylvania; the Dagger  Retina Service and the § Cataract and Primary Eye Care Service, Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania; and the parallel  Epidemiology Unit, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.

Objective.  Retinopathy of prematurity (ROP) is a leading cause of adverse visual outcomes in premature infants. Both laser photocoagulation and cryotherapy have been demonstrated in clinical trials to be efficacious in reducing the incidence of visual loss occurring secondary to threshold ROP. Visual data recently have become available concerning the long-term clinical efficacy of both treatments, as have data concerning the utility value of visual states in general. Accordingly, we undertook an analysis to ascertain the cost-effectiveness of laser photocoagulation and cryotherapy in the treatment of threshold ROP.

Design.  A computer simulation economic model is presented to evaluate the cost-effectiveness of cryotherapy and laser photocoagulation therapy, compared with the natural course of the disease, for treating premature infants with threshold ROP. The model applies long-term visual data from previous clinical trials, utility analysis, decision analysis, and economic principles, such as present value analysis, to account for the time value of money to arrive at a cost per quality-adjusted life-year (QALY) gained.

Outcome Measures.  Cost per QALY gained from laser therapy and cryotherapy.

Results.  Laser photocoagulation therapy for threshold ROP costs $678 1998 US dollars (at a 3% discount rate to account for the time value of money) for each QALY gained from treatment. Cryotherapy for the same disease costs $1801 per QALY at a similar discount rate.

Conclusions.  From the point of view of cost-effectiveness, laser therapy seems to have an advantage over cryotherapy for the treatment of threshold ROP.  Key words:  threshold retinopathy of prematurity, laser therapy, cryotherapy, cost-effectiveness.




This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
K. M. Jackson, K. E. Scott, J. Graff Zivin, D. A. Bateman, J. T. Flynn, J. D. Keenan, and M. F. Chiang
Cost-Utility Analysis of Telemedicine and Ophthalmoscopy for Retinopathy of Prematurity Management
Arch Ophthalmol, April 1, 2008; 126(4): 493 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
S Sharma, G C Brown, M M Brown, H Hollands, R Robins, and G K Shah
Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients
Br. J. Ophthalmol., May 1, 2002; 86(5): 493 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
M. M Brown, G. C Brown, S. Sharma, H. Hollands, and J. Landy
Quality of life and systemic comorbidities in patients with ophthalmic disease
Br. J. Ophthalmol., January 1, 2002; 86(1): 8 - 11.
[Abstract] [Full Text] [PDF]